MEDPMedpace Holdings, Inc.
Medpace Holdings, Inc. (MEDP) is a contract research organization that provides clinical trial services to pharmaceutical and biotechnology firms. The next catalyst is Oct 1, 2026 — Here's How Much $100 Invested in Medpace Holdings, Inc. Could Earn, which will test the company’s ability to deliver returns to investors amid shifting demand for clinical trial services.
- Revenue hit $2.68B in the latest period, up 20% YoY, but net income remains at $480.24M, with a net margin of 17.9%.
- Debt-to-equity ratio stands at 0.36x, suggesting a relatively balanced capital structure.
- Shareholders’ equity is $459.07M, with diluted EPS of $4.25, reflecting strong earnings power.
The Read
4% after missing book-to-bill expectations and facing project cancellations in Q4 2025, then rallied 6%.
The schedule
- Wed21Oct
This calendar update will provide investors with a summary of upcoming events, including the Q3 earnings release and potential regulatory updates.
- Thu22Oct
This earnings release will test the company's ability to maintain revenue growth and manage rising costs, particularly in the clinical trial services segment. The outcome will also reflect the impact of recent regulatory changes on operational efficiency and client retention.
- Tue9Feb
This earnings release will test the company's ability to sustain growth in the clinical trial services segment and manage rising costs, particularly in the context of regulatory changes.
- Tue20Apr
This earnings release will test the company's ability to maintain revenue growth and manage rising costs, particularly in the clinical trial services segment. The outcome will also reflect the impact of recent regulatory changes on operational efficiency and client retention.
- Tue20Jul
This earnings release will test the company's ability to maintain revenue growth and manage rising costs, particularly in the clinical trial services segment. The outcome will also reflect the impact of recent regulatory changes on operational efficiency and client retention.
Past
- Thu1Oct
This article will highlight potential returns from investing in MEDP, focusing on the company's growth in clinical trial services and its ability to capitalize on industry expansion.
- Wed29Apr
Actual outcome: Bull · $421.87 at outcome
Price reached or exceeded bull target ($455.00) at outcome date.
- Mon9Feb
Actual outcome: Bear · $416.04 at outcome
Medpace shares plummeted despite meeting EPS estimates because the company reported a significant book-to-bill miss and a surge in project cancellations that exposed pipeline fragility. This weakness in leading indicators, coupled with concerns over a stale backlog and cautious 2026 guidance, triggered a sharp valuation reset that sent the price well below the bear floor.
